NCT01445509 2026-01-15
Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
Clinical Trials
22 trialsNCT01187199 2025-10-27
Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT01061515 2025-09-17
Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer
Washington University School of Medicine
Phase 1 Active not recruiting
NCT06232902 2024-12-18
A Study to Compare the Pharmacokinetics and Safety of QL1101 and EU-Avastin® in Healthy Volunteers
Qilu Pharmaceutical Co., Ltd.
Phase 1 Completed
NCT02794571 2024-12-05
Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors
Genentech, Inc.
Phase 1 Completed
NCT01015222 2022-11-23
Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01197170 2021-01-22
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01633970 2020-10-08
A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Phase 1 Completed
NCT01514123 2020-09-17
Study of VGX-100 Administered Alone and Co-administered With Bevacizumab in Adult Subjects With Advanced Solid Tumors
Circadian Technologies Ltd.
Phase 1 Completed
NCT00095459 2019-12-17
BAY 43-9006 (Sorafenib) and Bevacizumab (Avastin) To Treat Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT01251926 2019-11-15
EZN-2208 (Pegylated SN-38) in Combination With Bevacizumab in Refractory Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00761644 2019-04-11
Doxil, Bevacizumab and Temsirolimus Trial
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01274624 2018-12-19
Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer
Oncolytics Biotech
Phase 1 Completed
NCT02640365 2017-01-31
DOUBLIRI
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 1 Completed
NCT00809133 2016-03-14
Trial Exploring Afatinib (BIBW 2992) + Paclitaxel (Part A), Afatinib + Paclitaxel + Bevacizumab (Part B), Afatinib + Carboplatin (Part C) and Afatinib+ Paclitaxel +Carboplatin(Part D) in Patients With Advanced Solid Tumours
Boehringer Ingelheim
Phase 1 Completed
NCT00710268 2015-01-14
Study to Assess Safety & Tolerability of AZD2281 in Combination With Bevacizumab in Patients With Advanced Solid Tumours
AstraZeneca
Phase 1 Completed
NCT01193595 2014-12-03
Dose-escalation, Safety, Pharmacokinetics Study of AVE8062 Combined With Bevacizumab in Patients With Advanced Solid Tumors
Sanofi
Phase 1 Completed
NCT02031991 2014-08-15
A Pharmacokinetic Study Comparing PF-06439535 And Bevacizumab In Healthy Male Volunteers (REFLECTIONS B739-01)
Pfizer
Phase 1 Completed
NCT00667485 2014-01-17
Rapamycin Plus Bevacizumab in Advanced Cancers
University of Chicago
Phase 1 Completed
NCT00395434 2011-10-31
Safety Study of Increasing Doses of Combretastatin in Combination With Bevacizumab (Avastin) in Patients With Advanced Solid Tumors
Mateon Therapeutics
Phase 1 Completed
NCT01271166 2011-01-06
Glivec® Plus m-FOLFOX Avastin® in Advanced Colorectal Cancer
Novartis
Phase 1 Terminated
NCT00611793 2009-01-23
PTK787/ZK222584 With Bevacizumab in Patients With Refractory and/or Advanced Malignancies
SCRI Development Innovations, LLC
Phase 1 Completed